
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company focusing on the development of products using its drug delivery platform technology. While facing challenges such as the recent CEO change and adjusted EPS estimates, the potential for approval and commercialization of CTx-1301 in mid-2026 may serve as a strong catalyst for the stock, with a current valuation that appears attractive and a BUY rating being maintained. Risks to consider include potential difficulties in gaining regulatory approval and market competition.
Bears say
Cingulate is primarily focused on developing therapeutics for ADHD and anxiety, which have a high prevalence and represent a large market opportunity. However, with numerous established competitors in the ADHD market and no current products on the market, Cingulate may have difficulty gaining a significant share of the market and generating substantial revenue. Additionally, the company's lack of diversification and dependence on the success of its two lead medications could make it vulnerable to market fluctuations and potential setbacks in clinical trials.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares